These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 19135319)

  • 1. Sex heterogeneity in pharmacogenetic smoking cessation clinical trials.
    Schnoll RA; Patterson F
    Drug Alcohol Depend; 2009 Oct; 104 Suppl 1(Suppl 1):S94-9. PubMed ID: 19135319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetics and smoking cessation improving outcomes in smokers at risk.
    Lerman CE; Schnoll RA; Munafò MR
    Am J Prev Med; 2007 Dec; 33(6 Suppl):S398-405. PubMed ID: 18021915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics and smoking cessation with nicotine replacement therapy.
    Ray R; Schnoll RA; Lerman C
    CNS Drugs; 2007; 21(7):525-33. PubMed ID: 17579497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smoking Cessation Pharmacotherapy Based on Genetically-Informed Biomarkers: What is the Evidence?
    Panagiotou OA; Schuit E; Munafò MR; Bennett DA; Bergen AW; David SP
    Nicotine Tob Res; 2019 Aug; 21(9):1289-1293. PubMed ID: 30690475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smoking cessation interventions for smokers with current or past depression.
    van der Meer RM; Willemsen MC; Smit F; Cuijpers P
    Cochrane Database Syst Rev; 2013 Aug; (8):CD006102. PubMed ID: 23963776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotine replacement therapy for smoking cessation.
    Silagy C; Mant D; Fowler G; Lancaster T
    Cochrane Database Syst Rev; 2000; (3):CD000146. PubMed ID: 10908462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventions for smoking cessation and reduction in individuals with schizophrenia.
    Tsoi DT; Porwal M; Webster AC
    Cochrane Database Syst Rev; 2010 Jun; (6):CD007253. PubMed ID: 20556777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do implementation issues influence the effectiveness of medications? The case of nicotine replacement therapy and bupropion in UK Stop Smoking Services.
    McEwen A; West R
    BMC Public Health; 2009 Jan; 9():28. PubMed ID: 19159473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders.
    Evins AE; Culhane MA; Alpert JE; Pava J; Liese BS; Farabaugh A; Fava M
    J Clin Psychopharmacol; 2008 Dec; 28(6):660-6. PubMed ID: 19011435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alcohol history and smoking cessation in nicotine replacement therapy, bupropion sustained release and varenicline trials: a review.
    Leeman RF; Huffman CJ; O'Malley SS
    Alcohol Alcohol; 2007; 42(3):196-206. PubMed ID: 17526629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which is the best primary medication for long-term smoking cessation--nicotine replacement therapy, bupropion or varenicline?
    Doggrell SA
    Expert Opin Pharmacother; 2007 Dec; 8(17):2903-15. PubMed ID: 18001252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular genetics of successful smoking cessation: convergent genome-wide association study results.
    Uhl GR; Liu QR; Drgon T; Johnson C; Walther D; Rose JE; David SP; Niaura R; Lerman C
    Arch Gen Psychiatry; 2008 Jun; 65(6):683-93. PubMed ID: 18519826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of bupropion in the management of smoking cessation.
    Jorenby D
    Drugs; 2002; 62 Suppl 2():25-35. PubMed ID: 12109933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interventions to increase adherence to medications for tobacco dependence.
    Hollands GJ; Naughton F; Farley A; Lindson N; Aveyard P
    Cochrane Database Syst Rev; 2019 Aug; 8(8):CD009164. PubMed ID: 31425618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotine replacement therapy for smoking cessation.
    Stead LF; Perera R; Bullen C; Mant D; Hartmann-Boyce J; Cahill K; Lancaster T
    Cochrane Database Syst Rev; 2012 Nov; 11():CD000146. PubMed ID: 23152200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.
    Lerman C; Jepson C; Wileyto EP; Epstein LH; Rukstalis M; Patterson F; Kaufmann V; Restine S; Hawk L; Niaura R; Berrettini W
    Neuropsychopharmacology; 2006 Jan; 31(1):231-42. PubMed ID: 16123753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis.
    Wu P; Wilson K; Dimoulas P; Mills EJ
    BMC Public Health; 2006 Dec; 6():300. PubMed ID: 17156479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.